Daniel Catenacci, MD, reviews the case of a 71-year-old man with gastric cancer.
Case: A 71-Year-Old Man With HER2+ Gastric Cancer
Initial Presentation
Clinical Workup
Treatment
T-DXd Combinations Effective in HER2+ Gastric and GEJ Cancer
September 14th 2024Findings from the DESTINY-Gastric03 study support the further exploration of the antibody-drug conjugate trastuzumab deruxtecan for the first-line treatment of patients with advanced HER2+ gastric, esophageal, and GEJ cancers.
Read More
Evorpacept Shows Promising Efficacy in HER2-Positive Gastric and GEJ Cancers
August 1st 2024The ASPEN-06 trial found that adding evorpacept to trastuzumab, ramucirumab, and paclitaxel significantly improved overall response rates and duration of response in patients with previously treated HER2-positive advanced gastric or gastroesophageal junction cancer.
Read More
Switch Maintenance Paclitaxel/Ramucirumab Prolongs Survival in Gastric Cancer
July 1st 2024Switch maintenance therapy with paclitaxel plus ramucirumab consistently prolonged survival regardless of clinical or molecular subgroups in HER2-negative disease controlled, metastatic gastric cancer.
Read More